Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Depreciation & Amortization (CF) (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Depreciation & Amortization (CF) data on record, last reported at $327000.0 in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 26.85% year-over-year to $327000.0; the TTM value through Dec 2025 reached $1.6 million, down 13.3%, while the annual FY2025 figure was $1.6 million, 13.3% down from the prior year.
  • Depreciation & Amortization (CF) reached $327000.0 in Q4 2025 per APLS's latest filing, down from $339000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $476000.0 in Q4 2023 and bottomed at $282000.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $403500.0, with a median of $423000.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 365.26% in 2021, then fell 26.85% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $373000.0 in 2021, then grew by 4.02% to $388000.0 in 2022, then grew by 22.68% to $476000.0 in 2023, then decreased by 6.09% to $447000.0 in 2024, then decreased by 26.85% to $327000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $327000.0 in Q4 2025, $339000.0 in Q3 2025, and $446000.0 in Q2 2025.